Abcam, ab259006, Human NT5C3A (PN-I) knockout A549 cell lysate

Size: 1Kit
NT5C3A KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon5.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon5.,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-NT5C3A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PN-I commonly known as Protease Nexin I serves as a serine protease inhibitor. It has a molecular mass of approximately 43 kDa. PN-I expression occurs predominantly in the nervous system and various cell types such as fibroblasts and endothelial cells. It regulates the activity of multiple proteases like thrombin urokinase and plasminogen activator. This regulation helps to ensure a balance in protease activity.
Biological function summary
PN-I plays a significant role in maintaining extracellular matrix homeostasis and modulating cellular processes like migration and proliferation. It is part of a complex with proteases that it inhibits forming stable complexes to neutralize their activity. Through its actions PN-I influences cell signaling and tissue remodeling having effects that are essential for physiological processes.
Pathways
PN-I interacts with the fibrinolytic and coagulation pathways. It modulates these pathways by inhibiting enzymes such as thrombin and urokinase impacting processes like blood clot formation and degradation. In the coagulation cascade PN-I effects relate closely to proteins like thrombin affecting blood homeostasis and ensuring a proper response to vascular injury.
PN-I has links to conditions such as thrombosis and tissue fibrosis. Alterations in PN-I expression or function can contribute to pathological states by disrupting protease regulation leading to excessive clot formation or tissue scarring. PN-I interacts with proteins involved in these diseases such as plasminogen activators highlighting its importance in maintaining proteolytic balance in tissues.